NoGeneST™ Anti-PAUF Aptamer, aPAUF aptamer-2 sodium

Name: NoGeneST™ Anti-PAUF Aptamer, aPAUF aptamer-2 sodium
SKU: NRYF-0625-HZ52
Rating: 5 (1 reviews)

[CAT#: NRYF-0625-HZ52]

A modified DNA aptamer that inhibits Pancreatic Adenocarcinoma Up-regulated Factor (PAUF) to suppress cancer cell migration.

Target:: Pancreatic Adenocarcinoma Up-regulated Factor (PAUF)

Type:: DNA

Datasheet MSDS Request COA

Certificate of Analysis Lookup
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number

Inquiry

Product Overview

Description

This is a 2'-fluoropyrimidine-modified DNA aptamer, engineered to specifically bind to and antagonize the Pancreatic Adenocarcinoma Up-regulated Factor (PAUF). By neutralizing PAUF, it inhibits the downstream signaling that promotes cancer cell migration and tumor growth, making it a valuable tool for studying the progression and potential treatments of pancreatic cancer.

Type

DNA

Properties

Size

1 mg; 5 mg; 10 mg

Appearance

Supplied as a lyophilized white to off-white solid.

Purity

>90%

Shipping

Room temperature

Storage

Powder Form: Stable for 3 years when stored at -20°C.
In Solvent: Stable for 6 months when aliquoted and stored at -80°C

Research Use Only

For Research Use Only

Target Details

Target

Pancreatic Adenocarcinoma Up-regulated Factor (PAUF)

Alternative Names

ZG16B (Zymogen granule protein 16 homolog B)

Gene ID

124220

Uniprot ID

Q96DA0

Target Overview

Pancreatic Adenocarcinoma Up-regulated Factor (PAUF) is a secretory protein that is highly overexpressed in pancreatic cancer and other malignancies. It functions as a key signaling molecule in the tumor microenvironment, promoting cancer progression by enhancing cell proliferation, migration, invasion, and angiogenesis (the formation of new blood vessels). PAUF interacts with various cell surface receptors to activate oncogenic signaling pathways, and its presence is often associated with metastasis and resistance to chemotherapy, making it a significant therapeutic target in oncology.

Publications